Ending the second long-running acquisition saga of the week, Cypress Bioscience has agreed to be bought by Ramius, who pulled in Royalty Pharma to help increase its offer from the original $4.00 per share to $6.50 per share in cash, raising the value of the deal to $255 million.
The $6.50 price represents a premium of around 160% to Cypress' share price on 16 July, the last trading day prior to the public disclosure of Ramius' unsolicited proposal.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?